Biosensors has entered into a licensing agreement with Eurocor for its drug-eluting balloon technology and related intellectual property rights in relation to the treatment of both coronary and peripheral artery disease. As a first step in this process, Biosensors will market and sell, under its own brand, drug-eluting balloons manufactured by Eurocor.
A Biosensors press release reported that the agreement involves three of of Biosensors-branded drug-eluting balloons: BioStream, BioPath 014, and BioPath 035. All three devices are drug-eluting balloon dilatation catheters designed for percutaneous transluminal angioplasty (PTA). BioStream has been developed for use in coronary arteries, while the other two devices have been optimised for the treatment of patients with peripheral arterial disease.
According to the press release, all three devices feature Eurocor’s proprietary coating technology delivering paclitaxel—an antirestenotic drug proven in drug-eluting balloon applications. The coating technology has been proven in several clinical studies performed by Eurocor, including the global Valentine I and II registries. The proprietary coating employed in these products is capable of delivering the antirestenotic drug consistently during very brief inflation times, while also minimising washout of the drug during delivery and placement of the drug-eluting balloon.
“We are delighted to have acquired a new range of leading drug-eluting balloons as a result of this licensing agreement with Eurocor”, commented Jeffrey B. Jump, president of Biosensors’ Cardiovascular Division. “These innovative devices will complement our existing portfolio of cardiac stents, and facilitate our entry into the peripheral vascular disease market.”
Following CE Mark approval currently anticipated within the next six weeks, BioStream, BioPath 014 and BioPath 035 will be launched in major European markets and selected regions in the Middle East, Africa and Asia.